Clinical trials: Acute Cellular Graft Rejection
Graft Rejection
A Pilot Study to Evaluate the Use of C1 Esterase Inhibitor (Human) in Patients With Acute Antibody-Mediated Rejection
The purpose of this research study is to evaluate the safety, effect, and pharmacology of C1 Esterase Inhibitor (human) in kidney transplant patients with acute Antibody-Mediated Rejection (AMR).
- Trial name
- NCT01147302
- Testing
- C1 Esterase Inhibitor (Human)
- Where
- 5 sites in United States, Germany
- Volunteers
- 18 people
- Sponsor
- Shire
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant
This phase II trial studies pentostatin and donor lymphocyte infusion in preventing graft rejection in patients who have undergone donor stem cell transplant.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Trial name
- NCT00096161
- Testing
- Cyclosporine, Mycophenolate Mofetil, Pentostatin
- Where
- 5 sites in United States, Italy
- Volunteers
- 36 people
- Sponsor
- Fred Hutchinson Cancer Center
Heart Transplant, Acute Graft Rejection
Stress Cardiac MRI for Evaluation of Nonspecific Allograft Dysfunction
The investigators will use cardiac MRI to measure the myocardial perfusion reserve and amount of myocardial edema and fibrosis in heart-transplant patients with nonspecific allograft dysfunction in contrast to those with normal…
- Conditions
- Heart Transplant, Acute Graft Rejection, Chronic Graft Rejection
- Trial name
- NCT02597543
- Testing
- Regadenoson, Gadolinium, Cardiac MRI
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Paul Kim
Renal Transplant Rejection
The Effect of Rituximab on the Development of Anti-Donor Antibodies
The aim of the study is to find out if Rituximab, which is an antibody against specific white cells involved in rejection, when combined with standard anti-rejection treatment can more effectively reverse the rejection process.
- Trial name
- NCT00695097
- Testing
- Rituximab, No Rituximab
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- University of California, San Francisco
Bronchiolitis Obliterans Syndrome, Graft Rejection
Azithromycin in Bronchiolitis Obliterans Syndrome
Preventive treatment with azithromycin reduces the prevalence fo Bronchiolitis Obliterans Syndrome after lung transplantation.
- Conditions
- Bronchiolitis Obliterans Syndrome, Graft Rejection, Lymphocytic Bronchiolitis, Respiratory Infection
- Trial name
- AZI001 (NCT01009619)
- Testing
- Azithromycin
- Where
- Belgium
- Volunteers
- 83 people
- Sponsor
- KU Leuven
Renal Transplant Rejection
Randomized Conversion of Calcineurin-Inhibitors in Renal Allograft Recipients
This study is being done to investigate the impact of changing immunosuppressive medications from tacrolimus (Prograf®) to sirolimus (Rapamune®) between 6 and 24 months post transplant.
- Trial name
- NCT00866879
- Testing
- Sirolimus, Demographic Data, Medical History, and Donor Data, Blood Draws for Control Group
- Where
- United States
- Volunteers
- 275 people
- Sponsor
- Northwestern University
Graft-Versus-Host Disease
Bridging Pediatric and Adult Biomarkers in Graft-Versus-Host Disease
This study is designed to collect longitudinal biological samples from patients after hematopoietic cell transplantation (HCT) cared for at multiple bone marrow transplant centers to validate biomarkers of both acute and chronic…
- Trial name
- NCT02194439
- Where
- United States
- Volunteers
- 415 people
- Sponsor
- Indiana University
Graft Rejection
Randomized Trial for Mixed Acute Rejection
This study is being conducted to determine how safe and effective using an immune cell (b cell) depleting therapy and/or Thymoglobulin is in patients with a kidney transplant who are experiencing certain types of rejection.
- Trial name
- NCT00771875
- Testing
- Rabbit Antithymocyte Globulin (RATG), Rituximab, Bortezomib
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- University of Cincinnati
Acute Cellular Graft Rejection, New Onset Diabetes After Transplant
Budesonide for Liver Transplant Immune Suppression
This is a pilot study that investigates the efficacy and safety of budesonide as an immune suppressing agent for liver transplant recipients in the early post-transplant period.
- Trial name
- NCT03304626
- Testing
- Budesonide 3Mg Capsule, Standard of Care Prednisone
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Cincinnati
Allografts, Rejection; Transplant, Kidney
A Study to Evaluate the Safety and Efficacy of Dual Costimulation Blockade With VIB4920 and Belatacept for Prophylaxis of Allograft Rejection in Adults Receiving a Kidney Transplant
The purpose of this study is to evaluate the efficacy, safety and tolerability of dual costimulation blockade with VIB4920 in combination of belatacept in adult male or female recipients of a renal allograft from a deceased…
- Conditions
- Allografts, Rejection; Transplant, Kidney, Transplant Rejection, Kidney Transplantation
- Trial name
- NCT04046549
- Testing
- Belatacept, VIB4920, Thymoglobulin
- Where
- 4 sites in United States
- Volunteers
- 25 people
- Sponsor
- Amgen
Acute Graft Rejection
Magnetic Resonance Elastography of Cardiac Transplant Rejection
Magnetic Resonance Elastography (MRE) for cardiac transplant patients.
- Trial name
- NCT02266914
- Testing
- Magnetic Resonance Elastography driver
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Ohio State University
Antibody-mediated Rejection, Hyperacute Rejection of Cardiac Transplant
The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation
All individuals who receive a heart transplant are at risk for developing antibody-mediated rejection (AMR). An antibody is a protein produced by the body's immune system when it detects a foreign substance, called an antigen.
- Conditions
- Antibody-mediated Rejection, Hyperacute Rejection of Cardiac Transplant, Left Ventricular Dysfunction, Cardiac Allograft Vasculopathy
- Trial name
- DUET (NCT02013037)
- Testing
- Eculizumab
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Cedars-Sinai Medical Center
Graft Rejection
Efficacy and Safety of Everolimus in Recipients of Heart Transplants to Prevent Acute and Chronic Rejection
This trial was to examine the impact of everolimus and reduced dose of cyclosporine on efficacy and safety compared to mycophenolate mofetil and a standard dose of cyclosporine in heart transplant recipients.
- Trial name
- NCT00300274
- Testing
- everolimus, mycophenolate mofetil, cyclosporine
- Where
- 64 sites in United States, Argentina and 13 more
- Volunteers
- 721 people
- Sponsor
- Novartis Pharmaceuticals
Hematologic Malignancies, Bone Marrow Transplant Rejection
Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow Malignancies
This study will evaluate the safety and effectiveness of stem cell transplantation in which the donor's T cells (a type of lymphocyte, or white blood cell) are removed and then added back.
- Trial name
- NCT00079391
- Testing
- allogeneic hematopoietic stem cell transplantation
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Delayed Graft Function, Acute Graft Rejection
Comparison of Sirolimus and Azathioprine in Lung Transplantation
The purpose of this study is to compare the safety and effectiveness of two different anti-rejection drug regimens.
- Trial name
- NCT00321906
- Testing
- azathioprine, sirolimus
- Where
- United States
- Volunteers
- 181 people
- Sponsor
- University of Chicago
Acute Graft Rejection, Diabetes
A Pilot Study Comparing the Use of Low-target Versus Conventional Target Advagraf
While the incidence of acute rejection and early graft loss have improved dramatically with the advent of newer immunosuppressant medications, improvements in long-term patient and allograft survival after kidney transplantation…
- Trial name
- Astellas (NCT01265537)
- Testing
- Tacrolimus
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- University of British Columbia
Acute Graft Rejection, Chronic Allograft Nephropathy
Study Cyclosporine (CsA) Versus Tacrolimus (Tacro) After Campath Induction in Kidney Transplantation
After alemtuzumab induction, followed with kidney transplantation, patients will be randomly assigned to receive either tacrolimus or cyclosporine microemulsion in combination with mycophenolates.
- Conditions
- Acute Graft Rejection, Chronic Allograft Nephropathy, Polyomavirus-related Transplant Nephropathy
- Trial name
- RSCS-Campath (NCT01346397)
- Testing
- cyclosporine or tacrolimus
- Where
- Russia
- Volunteers
- 170 people
- Sponsor
- Russian Academy of Medical Sciences